Federal Register / Vol. 71, No. 221 / Thursday, November 16, 2006 / Notices 66789 

events such as stroke and myocardial 

infarction, as well as cancer 

chemoprevention. 

Market: (1) An estimated 60 million 

people in the United States use NSAIDs 

regularly; (2) An estimated $5 billion are 

spent each year in the United States on 

prescription NSAIDs and approximately 

$2 billion are spent on over-the-counter 

NSAIDs. 

Development Status: Pre-clinical data 

is available. 

Inventors: Carlos Velazquez Martinez 

(NCI) et al. 

Related Publication: C Velazquez, PN 

Praveen Rao, EE Knaus. Novel 

nonsteroidal anti-inflammatory drugs 

possessing a nitric oxide donor diazen1-ium-1,2-diolate moiety: Design, 

synthesis, biological evaluation, and 

nitric oxide release studies. J Med 

Chem. 2005 Jun16;48(12):4061–4067. 

Patent Status: U.S. Provisional 

Application 60/794,421 filed 24 Apr 

2006 (HHS Reference No. E–186–2006/ 

0–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Norbert Pontzer, 

PhD, J.D.; 301/435–5502; 

pontzern@mail.nih.gov. 

Collaborative Research Opportunity: 

The Chemistry Section of the Laboratory 

of Comparative Carcinogenesis is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize the 

prodrugs described, as new and safer 

analgesic, anti-inflammatory, antithrombotic, and cancer 

chemopreventive agents. Please contact 

Betty Tong, Ph.D. at 301–594–4263 or 

tongb@mail.nih.gov for more 

information. 

Rat or Mouse Exhibiting Behaviors 

Associated With Human Schizophrenia 

Description of Technology: A newly 

developed animal model for 

schizophrenia is valuable for assaying 

pharmaceutical compounds for treating 

this disorder. Schizophrenia is a 

neuropsychiatric disorder characterized 

by cognitive deficits, bizarre behavior 

and/or hallucinations. Presently, there 

has been no satisfactory animal model 

for testing promising therapies for this 

disorder. 

This invention provides a unique and 

surprisingly accurate animal model for 

human schizophrenia. The animals are 

brain damaged while prepubescent. The 

brain damage consists of a ventral 

hippocampus lesion induced by 

exposure of the hippocampus region to 

a neurotoxin. When the animal reaches 

puberty, abnormal behavior and a 

number of biological phenomena 

associated with schizophrenic 

symptoms emerge. 

The present invention also provides 

methods of assaying the antischizophrenic potential of 

pharmaceutical compositions. The 

methods involve (a) Inducing or creating 

a lesion in the ventral hippocampus of 

a prepubescent mammal, (b) nurturing 

or raising the mammal until 

postpuberty, (c) administering to the 

mammal a pharmaceutical composition 

thought to have anti-schizophrenic 

properties; and (d) determining the 

mammal’s response to the 

pharmaceutical composition. The antischizophrenic potential of the 

pharmaceutical composition is assessed 

by objectively measuring the mammal’s 

behavior following administration of the 

pharmaceutical composition. The 

behaviors which are measured typically 

include the following: locomotor 

activity in a cage, in unfamiliar or novel 

environments, after injection or 

administration of drugs (e.g., 

amphetamines), after mild electric 

shock, after exposure to sensory stimuli 

(e.g., noise), in water (swim test), after 

immobilization, in social interactions, 

and in various learning and reward 

paradigms. 

The neurotoxin used can be selected 

from a number of known agents which 

lethally affect neurons usually, but not 

exclusively, by over-exciting their 

glummate receptors. Examples of such 

neurotoxins include ibotenic acid, Nmethyl-D-aspartic acid, kainic acid, 

dihydrokainate, DL-homocysteate, Lcysteate, L-aspartate, L-glutamate, 

colchicine, ferric chloride, omegaconotoxin GVIA, 6-hydroxy-dopamine. 

Advantage: This is the first model 

showing postpubertal emergence of 

abnormalities similar to those reported 

in schizophrenia. 

Applications: (1) Animal model for 

human schizophrenia; (2) Screening 

methods for Anti-schizophrenics. 

Development Status: Validated, well 

characterized and ready for use. 

Inventors: Daniel R. Weinberger, 

Barbara K. Lipska, and George E. Jaskiw 

(NIMH). 

Publications: 

1. AHC Wong, BK Lipska, O Likhodi, 

E Boffa, DR Weinberger, JL Kennedy, 

HHM Van Tol. Cortical gene expression 

in the neonatal ventral-hippocampal 

lesion rat model. Schizophr Res. 2005 

Sep 15;77(2–3):261–270. 

2. BK Lipska. Using animal models to 

test a neurodevelopmental hypothesis of 

schizophrenia. J Psychiatry Neurosci. 

2004 Jul;29(4):282–286. 

3. BK Lipska and DR Weinberger. To 

model a psychiatric disorder in animals: 

schizophrenia as a reality test. 

Neuropsychopharmacology 2000 

Sep;23(3):223–239. 

4. BK Lipska, GE Jaskiw, DR 

Weinberger. Postpubertal emergence of 

hyperresponsiveness to stress and to 

amphetamine after neonatal excitotoxic 

damage: a potential animal model of 

schizophrenia. 

Neuropsychopharmacology 1993 

Aug;9(1):67–75. 

Patent Status: U.S. Patent No. 

5,549,884 issued 27 Aug 1996 (HHS 

Reference No. E–013–1993/0–US–01). 

Availability: Available for nonexclusive licensing. 

Licensing Contact: Norbert Pontzer, 

Ph.D., J.D.; 301/435–5502; 

pontzern@mail.nih.gov. 

Dated: November 8, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–19408 Filed 11–15–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; ENCODE RFA. 

Date: December 6–7, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Rudy O. Pozzatti, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Human Genome 

Research Institute, National Institutes of 

Health, Bethesda, MD 20892, 301 402–0838. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 


pwalker on PROD1PC61 with NOTICES
66790 Federal Register / Vol. 71, No. 221 / Thursday, November 16, 2006 / Notices 

Dated: November 7, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9209 Filed 11–15–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Neural Tube 

Defects. 

Date: November 28, 2006. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 5B01, Rockville, 

MD 20852, (Telephone Conference Call). 

Contact Person: Anne Krey, Scientific 

Review Administrator, Division of Scientific 

Review, National Institute of Child Health 

and Human Development, National Institutes 

of Health, Bethesda, MD 20892, 301–435–

6908. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel Children Living in 

Rural Poverty: The Continuation of the 

Family Life Project. 

Date: November 30, 2006. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Jefferson, 2500 Calvert Street, 

NW., Washington, DC 20037. 

Contact Person: Marita R. Hopmann, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, 6100 

Building, Room 5B01, Bethesda, MD 20892, 

(301) 435–6911, hopmannm@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, A Prospective Study 

of Diet and Fibroids in Black Women. 

Date: November 30, 2006. 

Time: 10 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 5B01, Rockville, 

MD 20852, (Telephone Conference Call). 

Contact Person: Jon M. Ranhand, PhD, 

Scientist Review Administrator, Division of 

Scientific Review, National institute of Child 

Health and Human Development, NIH, 6100 

Executive Boulevard, Room 5B01, Bethesda, 

MD 20892, (301) 435–6884, 

ranhandj@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel Environmental & 

Biological Variation and Language Growth. 

Date: December 5, 2006. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Jefferson Hotel, 1200 Sixteenth 

Street, NW., Washington, DC 20036. 

Contact Person: Marita R. Hopmann, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health, and Human Development, 6100 

Building, Room 5B01, Bethesda, MD 20892, 

(301) 435–6911, hopmannm@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel Translational 

Analyses of Chronic Aberrant Behavior 

Across the Life Span. 

Date: December 6, 2006. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Marita R. Hopmann, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health, and Human Development, 6100 

Building, Room 5B01, Bethesda, MD 20892, 

(301) 435–6911, hopmannm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: November 7, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9210 Filed 11–15–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Drug Testing Advisory Board; Notice 

of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given of the meeting of 

the Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

Drug Testing Advisory Board in 

December 2006. 

A portion of the meeting will be open 

and will include, but not limited to, a 

Department of Health and Human 

Services drug testing program update, a 

Department of Transportation drug 

testing program update, a Nuclear 

Regulatory Commission drug testing 

program update, an update on the pilot 

performance testing programs for hair 

and oral fluid, results from a Medical 

Review Officer data source, and results 

from a study on the external 

contamination of hair with cocaine. 

Attendance by the public will be 

limited to space available. Public 

comments are welcome. Please 

communicate with Dr. Donna Bush, 

Executive Secretary (see contact 

information below), to make 

arrangements to comment or to request 

special accommodations for persons 

with disabilities. 

The Board will also meet to develop 

the final revisions to the proposed 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs that 

were published in the Federal Register 

on April 13, 2004 (69 FR 19673). This 

meeting will be conducted in closed 

session since discussing these issues in 

open session will significantly frustrate 

the Department’s ability to develop the 

revisions to the Mandatory Guidelines. 

The HHS Office of General Counsel 

made the determination that such 

matters are protected by exemption 9(B) 

of section 552b(c) of title 5 U.S.C. and, 

therefore, may be closed to the public. 

To facilitate entering the building for 

the open session, public attendees are 

required to contact Mrs. Giselle Hersh, 

Division of Workplace Programs, 1 

Choke Cherry Road, Room 2–1042, 

Rockville, MD 20857, 240–276–2605 

(telephone) or by e-mail to 

Giselle.Hersh@samhsa.hhs.gov. 

Substantive program information and 

a roster of Board members may be 

obtained by contacting Dr. Bush or by 

accessing the SAMHSA workplace Web 

site (http://workplace.samhsa.gov). The 

transcript for the open session will be 

available on the SAMHSA workplace 

Web site within 3 weeks after the 

meeting. 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration Drug Testing Advisory 

Board. 

Meeting Date: December 12–13, 2006. 

Place: SAMHSA Building, Rock Creek 

Room 1, Choke Cherry Road, Rockville, 

Maryland 20850. 

Type: Open: December 12, 2006; 8:30 

a.m.–4:30 p.m. 


pwalker on PROD1PC61 with NOTICES